ment of suspected or proven systemic fungal infections such as invasive aspergillosis, zygomycosis, and candidiasis. To treat systemic fungal infections in children, the dose used at St. Jude Children's Research Hospital in patients weighing less than 34 kg is 18-24 mg/kg daily, given orally in 4 divided doses. Usually, patients aged 13 years or older or those weighing 34 kg or more are treated with 800 mg daily, given orally in 4 divided doses. All patients are encouraged to take the medication with high-fat meals or acidic beverages.
The bioavailability and systemic exposure of posaconazole are affected by food and some medications. When posaconazole is administered with a nutritional supplement or high-fat meals, its bioavailability is significantly increased. 5 Conversely, medications that increase gastric pH, such as proton pump inhibitors and histamine H 2 -blockers, have been shown to decrease posaconazole exposure. 5 Numerous studies have found a correlation between plasma exposure and response. When posaconazole plasma concentrations were greater than or equal to 0.7 µg/mL, the proportion of clinical responders increased in a cohort of 67 patients with invasive aspergillosis who received posaconazole for salvage treatment. 2 In another study, 9 patients received posaconazole for treatment of invasive fungal infections. Patients who responded to treatment had higher posaconazole concentrations (median 0.955 µg/mL) than did patients in whom therapy failed (median 0.436 µg/mL). 6 Posaconazole shows significant intrapatient variability, mostly as a result of erratic absorption. In addition, posaconazole exhibits a concentration-effect relationship. 7 For these reasons, some authors advocate monitoring to ensure that adequate drug concentrations are present. [7] [8] [9] [10] [11] [12] Even though a posaconazole target concentration has not been identified for treatment of invasive fungal infections, 11,12 some authors recommend a provisional target of 0.7 µg/mL, with escalation to 1.25 µg/mL if response is poor. 11 Based on the data available for patients aged 13 years of age or older, a posaconazole target concentration of 0.7 µg/mL or greater was chosen for this study.
The objective of this study was to determine whether the current dosing approach used at St. Jude Children's Research Hospital achieves posaconazole plasma concentrations greater than or equal to 0.7 µg/mL. methods definitions Adolescents and young adults were defined as patients whose age ranged from 12 to 24 years based on the World Health Organization and the Youth Advisory Council Act (1989) definition. A patient's study period was defined as the time from the first posaconazole dose until a dosage change, posaconazole discontinuation, or the end of the observation period. Empiric treatment was defined as therapy given to treat a suspected or probable fungal infection. Treatment was defined as therapy when administered for a fungal infection that was proven by either positive culture or pathologic findings. Progression of infection was defined as evidence of progressive fungal disease based on a composite of clinical, radiologic, and/or mycologic criteria while the patient received therapeutic doses of the drug. Safety and tolerability were assessed for all patients included in the study. The St. Jude institutional review board approved this study.
data collection and assessment
Retrospective clinical data were obtained for all patients who received posaconazole from January 1, 2007, to August 22, 2010. Only patients who received posaconazole for treatment of fungal infections and who had at least 1 posaconazole plasma concentration measurement were included in the study. From 2007 through February 2010, concentrations were assessed by send-out to a reference clinical laboratory (University of Texas Health Science Center, Fungus Testing Laboratory, San Antonio, TX). Starting in March 2010, posaconazole concentrations were measured onsite in St. Jude Children's Research Hospital's clinical pharmacokinetic laboratory. Both laboratories use high-performance liquid chromatography with ultraviolet detection to measure posaconazole concentrations. Posaconazole plasma concentrations from 5 specimens were analyzed at the onsite laboratory and the send-out laboratory. The average percent bias between measurements was 5.1% (range 2.7-24.6%). This 5% difference between methods is well within the total error expected for these assays (maximum total error allowed 25%).
The first concentration obtained for each patient during the study period was used for analysis; having achieved steady-state was not a prerequisite for inclusion of the data in the analysis. Posaconazole was considered to have achieved a steady-state plasma concentration after at least 7 days of dosing. 1 For hospitalized patients, trough concentrations were obtained. When posaconazole concentrations were obtained in the outpatient clinics, patients were instructed not to ingest the morning posaconazole dose until the sample had been obtained. Adverse drug effects were characterized as described in National Cancer Institute Common Terminology Criteria version 3.0. 13 Information collected included patient demographics, primary diagnosis, posaconazole dosing, indication for therapy (prophylaxis, empiric treatment, or treatment), selected concomitant medications (eg, H 2 -blockers, metoclopramide, phenytoin, proton pump inhibitors, and rifabutin or rifampin), adverse effects (eg, increase in liver function test [LFT] results, QTc prolongation, rash, nausea, and vomiting), and posaconazole plasma concentration.
statistical analysis
Data were summarized and the characteristics of patients with low plasma concentrations were compared with those of patients who achieved target concentrations (defined as posaconazole plasma concentration of 0.7 µg/mL or greater). Because of the small sample size, the Mann-Whitney U test and Fisher exact test were used to analyze the data. A 2-tailed p value of less than 0.05 was considered statistically significant. Statistical computations were performed using Statistica version 10 (StatSoft, Inc.).
results

Patient characteristics
A total of 118 patients received at least 1 dose of posaconazole during the study period; 33 received posaconazole for the treatment of suspected (19; 57.5%) or proven infections (14; 42.4%) and had at least 1 posaconazole plasma concentration measurement ( Table 1 ). The median age of patients in this analysis was 11.5 years (range 0.5-23.2 years). Leukemia and lymphoma were the most common underlying conditions (81.8%). Most (69.7%) posaconazole concentrations were obtained at steady-state ( Table 2 ). The median posaconazole plasma concentration in these patients was 0.72 µg/mL (range 0.22-2.04). Three of the 10 patients who had a posaconazole concentration measured before 7 days of therapy had subtherapeutic levels.
Four study patients experienced infection progression as described below. Twelve of the study patients received concomitant medications with the potential to affect posaconazole plasma concentrations.
Twelve of 33 patients had plasma concentrations below 0.7 µg/mL. These patients received significantly lower dosages of posaconazole referenced to body weight compared to patients with concentrations of 0.7 µg/mL or greater (median 12.9 mg/kg/day vs 20 mg/kg/day, p = 0.02) ( Table 3) .
Twenty-one patients were younger than 13 years and 12 were 13 years or older (Table 4 ). When the data were analyzed by age group, 16 of 21 (76.2%) of those younger than 13 years achieved a target posaconazole concentration, versus 5 of 12 (41.6%) of the patients aged 13 years or older (p = 0.06, Fisher exact test). Comparison of the median plasma concentrations in these 2 groups did not reveal a statistically significant difference. Patients younger than 13 years received higher median posaconazole dosages referenced to body weight (p < 0.001) ( Table 4 ).
clinical course
Nineteen patients received posaconazole as empiric therapy, with only 1 patient experiencing a progression of infection. The remaining 14 patients received therapy for a proven fungal infection. Three of the 14 experienced a fungal progression.
Of the patients who experienced fungal infection progression, age, posaconazole plasma concentration, and dosage were not associated with progression (all p > 0.05). One patient with infection progression was being treated for disseminated Aspergillus infection in the eyes and the lungs. This patient had positive cultures from vitreous fluid and bronchoalveolar lavage. At the beginning of the patient's treatment with posaconazole, Aspergillus galactomannan antigen assay results were negative; however, after 1.5 months of posaconazole therapy, Aspergillus antigen testing results became positive. The initial posaconazole concentration in this patient was 0.2 µg/mL. Although this patient achieved a concentration of 0.72 µg/mL after 2 months of therapy, a computed tomography (CT) scan showed that the infection had progressed, and therapy was switched to liposomal amphotericin B. The patient died of fungal infection.
Another patient was receiving posaconazole, liposomal amphotericin B, and micafungin for proven disseminated Candida albicans and C. famata infections that started on the hard palate and spread to the left maxilla, nose, and left 978 ■ The Annals of Pharmacotherapy ■ 2013 July/August, Volume 47 theannals.com VA Bernardo et al. orbit. This patient died almost 2 months after starting treatment with antifungal combination therapy. This patient had 2 posaconazole plasma concentrations, 1.63 µg/mL and 0.55 µg/mL, measured 12 and 20 days, respectively, after posaconazole therapy was started. A third patient developed a fungal lesion on the left kidney 7 months after starting posaconazole therapy for the treatment of proven pulmonary zygomycete infection. After resection of the fungal kidney lesion, the patient continued posaconazole therapy and was alive 11 months after the surgery. The initial posaconazole plasma concentration in this patient was 0.7 µg/mL. All subsequent posaconazole concentrations were above the target level.
The treatment for a fourth patient who was receiving posaconazole for suspected fungal infection was switched to voriconazole after a CT scan demonstrated enlarging pulmonary nodules, despite treatment with posaconazole for nearly a month. The posaconazole plasma concentration in this patient was 0.92 µg/mL.
safety and tolerability
Of the 33 patients included in this study, 7 (21%) experienced adverse effects. Two patients developed grade II liver toxicity during therapy and 5 developed grade III liver toxicity. A Naranjo score of 3 was obtained for each patient, suggesting that posaconazole could possibly have caused the development of liver toxicity. However, all of these patients were receiving other medications that could have been responsible for the increase in LFT values. All adverse effects resolved while therapy continued.
The 2 patients with grade II liver toxicity experienced LFT elevation of 3-5 times the upper limit of normal without further symptomatology. This toxicity was noted at 5 days and 6 days, respectively, following initiation of therapy The laboratory values returned to within the normal range within 2-5 days while therapy continued.
Five patients with grade III liver toxicity experienced elevation of LFT values greater than 5 times the upper limit of normal without further symptomatology. This toxicity was noted after 10 days (2 cases), 15 days, 1.5 months, and 9 months of therapy, respectively. In each case, the laboratory values returned to within the normal range between 3 and 20 days. This resolution occurred while therapy was continued.
Two patients had elevated LFT results prior to starting posaconazole; therefore, these patients were not considered to have experienced adverse effects from posaconazole. One of the patients with liver toxicity also had a grade III rash. However, the rash was not thought to be related to posaconazole, and posaconazole treatment was continued. The median dosage and median posaconazole plasma concentrations for patients who experienced adverse effects were not significantly different from those of patients who did not experience adverse effects. No other adverse events, such as nausea, vomiting, rash, or QTc prolongation, were recorded in the medical record.
concomitant medications
Twelve patients received either an H 2 -blocker or a proton pump inhibitor, both of which have been shown to decrease the absorption of posaconazole. 3 None of the patients received metoclopramide, phenytoin, rifabutin, or rifampin. There were no statistically significant differences in the median body weight-based dosages (p = 0.42) or posaconazole plasma concentrations (p = 0.8) in patients receiving concomitant medications versus patients not receiving concomitant medications.
discussion
Our objective was to report on the relationship between the prescribed dosage of posaconazole used in pediatric and young adult oncology/hematology patients, patient age, and observed plasma concentrations. Because drug dosages for patients aged 13 years or older were determined using the FDA-approved recommendations, the patients received a lower weight-based dosage of posaconazole and
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The Annals of Pharmacotherapy ■ 2013 July/August, Volume 47 ■ 979 theannals.com achieved lower plasma concentrations than did patients younger than 13 years. Our assessment relied on the results of analyses conducted in the course of clinical care. Trough (predose) concentrations were analyzed, and we limited our analysis to the first clinical concentration obtained; 14 of 33 (42.4%) patients had only 1 concentration determined during the course of treatment. Using the predose concentration is justified, since data demonstrate that there is minimal vari-ability during the course of the day for most patients. 14 We did include 10 patients whose concentrations were measured before 7 days of therapy had elapsed. These were included because the reported half-life of posaconazole ranges from 20 to 66 hours 1 and children routinely demonstrate shorter halflives compared to adults, thus allowing for initial concentrations to be obtained earlier. Posaconazole concentrations were not reported in this study. 16 The median age (11.5 years) in our study was similar to the median age in the study conducted by Lehrnbecher et al. 16 and younger than that in the Krishna et al. 15 study. The median dosage in our study (17 mg/kg/day) was similar to the median dosage in the study conducted by Krishna et al. 15 but lower than that reported by Lehrnbecher et al. 16 We found that lower dosages were related to lower plasma concentrations. Based on these plasma concentrations, patients aged 13 years or older appear to require more aggressive dosing than is currently recommended.
Although target concentrations for posaconazole have not been firmly established, [9] [10] [11] [12] 17 several studies have demonstrated the relationship between clinical response and plasma concentration. 2,6, 18 In an open-label investigational study, Walsh et al. reported that patients with refractory invasive aspergillosis who had an average steady-state posaconazole concentration of 1.25 µg/mL had higher clinical response (75%) than did those with an average steady-state concentration of 0.13 µg/mL (24%). Additionally, 53% of patients with an average steady-state concentration between 0. µg/mL and 0.7 µg/mL responded to treatment. 2 Another study evaluated the clinical efficacy of posaconazole among 86 patients who received posaconazole for prophylaxis and treatment of fungal infections. 6 Of the 86 patients, 72 (84%) received posaconazole for prophylaxis and 14 (16%) for the treatment of invasive fungal infections. Among the patients who received posaconazole for prophylaxis, 12 had breakthrough fungal infections. The median posaconazole concentration in these 12 patients was 0.289 µg/mL, which was significantly lower than the concentration in those who did not develop breakthrough infections (median 0.485 µg/mL; p < 0.01). Of the 14 patients who received posaconazole for treatment of invasive fungal infection, 9 were evaluated for treatment outcome. Therapy failed in 4 of these 9 patients. The median posaconazole concentration in these 4 patients was 0.436 µg/mL, which was lower than for those who responded to treatment (median 0.955 µg/mL; p = 0.19). 6 In addition, an exposure-response analysis of 2 randomized, active-controlled clinical studies revealed that a posaconazole plasma concentration of 0.7 µg/mL or greater is necessary to minimize the incidence of breakthrough infections. 18 Using the data from the studies by Walsh et al. 2 and Dolton et al., 6 we selected 0.7 µg/mL as our target concentration. Although we were unable to demonstrate a relationship between clinical outcome and plasma concentrations, we demonstrated a relationship between dose and patients who achieved target level posaconazole concentrations. Indeed, several factors have been shown to affect posaconazole pharmacokinetics, including gastric pH, dosing frequency, prandial state, timing of food consumption, gastric motility, underlying disease, and mucositis. 5,19,20 Diarrhea has been identified as one factor correlated with reduced posaconazole absorption. 21 In addition, several commonly used drugs, including omeprazole and ranitidine, can alter the pharmacokinetics. However, we were unable to demonstrate a relationship between posaconazole concentrations and use of medications known to modify posaconazole pharmacokinetics. Because of the known influences of dietary factors on posaconazole absorption, we attempted to explore the relationship between dietary behavior and plasma concentrations. Unfortunately, adequate dietary records were not available for the study. Finally, we did not examine the presence of diarrhea as a possible contributor to reduced concentrations.
Because posaconazole absorption is affected by several factors, such as food, gastric pH, dosing frequency, mucosal health, and gastric motility, 5,19 there is significant interpatient variability in the pharmacokinetic parameters. 9, 17 Therapeutic drug monitoring may be crucial in the care of patients receiving posaconazole, especially in those with suspected treatment failure, infections at sanctuary sites, infections due to drug-resistant organisms, mucositis, malabsorption, and in those unable to take posaconazole with high-fat food. 8, 9, 22 Other studies have demonstrated that many adults treated with posaconazole, including those who are neutropenic, fail to achieve desired plasma concentrations. 12, 23 Bryant et al. also found that increasing the dose of the drug failed to result in an increase in concentrations in 4 of 6 neutropenic hematologic malignancy patients with low concentrations. 23 Our data and those of Krishna et al. 15 draw attention to the question of whether use of a higher weight-based dosage in adolescents may more frequently result in higher plasma concentrations.
In our study, posaconazole was well tolerated, with the most common adverse effect being a transient increase in LFT values that resolved while therapy continued. This result is concordant with those of other studies assessing the safety of posaconazole in pediatric patients. 15, 16 Lehrnbecher et al. reported that 73% of their patients experienced some adverse events. 16 The most commonly reported adverse events were fever, nausea and/or vomiting, abdominal pain, diarrhea, headache, skin eruptions, and elevated LFT results. The frequent increases in laboratory hepatic parameters were attributed to the multiple concomitant medications that these patients received. Because therapeutic drug monitoring was not performed by Lehrnbecher et al. , no associations can be made regarding the incidence of liver toxicity and posaconazole plasma concentrations. Similarly, in the study conducted by Krishna et al., the most common adverse events were nausea, vomiting, abdominal pain, and headache. 15 In addition, 2 patients (16%) had elevated LFT results. However, both of these elevations were deemed unlikely to be related to posaconazole treatment. 16 There were several limitations of our study. Because this was a retrospective study, we were unable to assess adherence to posaconazole therapy. It is possible that adolescents were less adherent to drug therapy, thereby contributing to the lower concentrations noted in this age group. Furthermore, there was a lack of documentation of nutritional intake in the outpatient setting, making conclusions about the impact of diet difficult to ascertain. Patients with a subtherapeutic concentration may have had poor oral intake. Ten of 33 patients had a posaconazole concentration measured before steady-state was achieved. Although only 3 patients had subtherapeutic concentrations, the concentrations may have been higher had posaconazole been measured at steady-state. Lastly, we were unable to find a relationship between drug concentration and outcome. This may be related to the fact that we looked at the first posaconazole plasma concentration.
In conclusion, the current institutional dosing approach resulted in therapeutic posaconazole plasma concentrations more frequently in patients younger than 13 years than in those 13 years or older. This difference in plasma concentrations was likely the result of capping adolescent and young adult dosing at the suggested maximum adult dose. However, several other factors such as diet, concomitant medications, and adherence may have affected posaconazole concentration. In both age groups, therapeutic concentrations were not achieved in some patients. Larger studies are needed to determine appropriate dosing and therapeutic drug monitoring in pediatric patients. Until such data are available, we suggest routine therapeutic drug monitoring in all patients to confirm that adequate concentrations have been achieved. Furthermore, we recommend evaluation of the utility of dosing adolescent and young adult patients based on body size, potentially resulting in exceeding the usually recommended maximum adult dose. theannals.com TRASFONDO: La información sobre el uso de posaconazol para el tratamiento de infecciones fúngicas sistémicas en niños, adolescentes, y adultos jóvenes con cáncer es limitada. En el hospital St. Jude Children's Research, en Memphis, Tennessee, la dosis recomendada de posaconazol en pacientes de menos de 34 kg es de 18-24 mg/kg/día distribuida en 4 tomas. Para pacientes con más de 13 años o de más de 34 kg, la dosis recomendada es de 800 mg/día por vía oral distribuida en 4 tomas.
OBJETIVO: Este estudio se llevó a cabo para determinar si las pautas de dosificación actuales de posaconazol obtienen las concentraciones plasmáticas diana de posaconazol de ≥ 0.7 µg/mL.
MÉTODOS:
Examinamos los datos procedentes de pacientes tratados con posaconazol y con al menos una medicación de la concentración plasmática de posaconazol.
RESULTADOS:
Se analizaron los datos procedentes de 33 pacientes que recibieron posaconazol para el tratamiento de infecciones fúngicas. La edad media de los pacientes fue de 11.5 años (rango 0.5-23.2 años). Vientiuno de los 33 pacientes (63.6%) presentaron concentraciones de posaconazol de ≥ 0.7 µg/mL (media 1.4 µg/mL; rango 0.7-2.98 µg/mL) en la primera medición. La dosis media de posaconazol según el peso corporal total en estos pacientes fue de 20 mg/kg/día. Los pacientes con concentraciones < 0.7 µg/mL, (media 0.4 µg/mL; rango 0.025 -0.69 µg/mL) recibieron dosis menores de posaconazol al correspondiente al peso corporal (media 12.9 mg/kg/día; p = 0.02). De los 12 pacientes con concentraciones < 0,7 µg/mL, 7 (58.3%) eran mayores de 13 años.
CONCLUSIONES: El enfoque actual de dosificación para posaconazol produjo concentraciones plasmáticas terapéuticas con más frecuencia en pacientes menores de 13 años que en pacientes mayores de 13 años. Esta diferencia puede estar relacionada con la práctica de aumentar las dosis de adolescentes y adultos jóvenes hasta la dosis diaria máxima recomendada para adultos. Por este motivo, recomendamos la dosificación según el peso en todos los pacientes pediátricos, adolescentes y adultos jóvenes con cáncer, además de la realización de un seguimiento rutinario del fármaco terapéutico en todos los pacientes para asegurar unas concentraciones plasmáticas adecuadas.
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